ClinicalTrials.gg
CompletedNCT06799286Updated Sep 24, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer

A Phase 1 interventional study of BMS-986489 in Small Cell Lung Carcinoma, sponsored by Bristol-Myers Squibb. Completed at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb — 2 open to participants now, 2 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Bristol-Myers Squibb.

Enrollment
15th of 17
10 · median 92
Started
2025
with 1 other
Phase 1
6 of 19
none open now
Registered
18th of 19
by date

Among the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, this one is the 15th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 1, and was the 18th registered.

Small Cell Lung Carcinoma

1,302 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of BMS-986489 in Chinese participants with R/R SCLC (Relapsed/Refractory Small Cell Lung Cancer).

03

Conditions studied

  • Small Cell Lung Carcinoma

Keywords

  • BMS-986489
  • atigotatug
  • BMS-986012
  • SCLC
  • fucosyl-GM1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participants must have or cytologically documented SCLC (small cell lung cancer). Participants with either limited or extensive disease stage at the initial diagnosis, who have received at least one , are eligible.

i) For initial limited stage (LS) SCLC:.

A. Those who progressed or recurred after more than 6 months treatment-free interval following treatment of curative surgical resection, systemic therapy, or radiotherapy, and subsequently received at least one line of systemic therapy to treat the recurrence or progression, and then progressed, or were intolerant to the prior systemic therapy per the assessment of investigators, these participants will be eligible, or

B. Who progressed or recurred within 6 months after treatment of curative surgical resection, systemic therapy, or radiotherapy, no matter if these participants have received subsequent systemic therapy, these participants will be eligible.

ii) For initial extensive stage (ES) SCLC, participants must have received at least one line of platinum-based systemic therapy (with/without immunotherapy), and then progressed, or been intolerant to the prior systemic therapy per the assessment of investigators.

A. Note: 1) For ES-SCLC with only one line of platinum-based regimen as well as chemotherapy-free interval is more than 6months when progression, only when participants refuse or are ineligible for re-treatment with platinum-based doublet per the assessment of investigators, these participants will be eligible. 2) If participants receive re-treatment with a platinum-based regimen, it is considered a second line of therapy.

  • Participants must have a of ≥12 weeks.
  • Participants must have at least 1 outside the central nervous system (CNS) by computed tomography (CT) or magnetic resonance imaging (MRI) per version 1.1 (RECIST v1.1) criteria.
  • (ECOG) performance status (PS) of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Untreated symptomatic .
  • .
  • Pleural effusion which cannot be controlled with appropriate interventions.
  • -related superior vena cava syndrome.
  • Participants with an active, known or suspected, disease.
  • Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to first study treatment.
  • Unresolved toxicity from prior anti-tumor therapy.
  • Prior treatment with an anti-fuc-GM1 therapy or any other drug specifically targeting fuc-GM1.
  • Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    BMS-986489

    Drug: BMS-986489

Interventions

This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 19 months after last participant's first treatment

  2. Number of participants with Serious AEs (SAEs)

    Time frame: Up to 19 months after last participant's first treatment

  3. Number of participants with AEs leading to discontinuation of study treatment

    Time frame: Up to 19 months after last participant's first treatment

  4. Number of participants with select AEs

    Time frame: Up to 19 months after last participant's first treatment

  5. Number of participants with immune-mediated AEs (IMAEs)

    Time frame: Up to 19 months after last participant's first treatment

  6. Number of deaths

    Time frame: Up to 19 months after last participant's first treatment

  7. Number of participants with laboratory abnormalities

    Time frame: Up to 19 months after last participant's first treatment

  8. Maximum observed concentration (Cmax) for BMS-986012

    Time frame: Up to 19 months after last participant's first treatment

  9. Time of maximum observed concentration (Tmax) for BMS-986012

    Time frame: Up to 19 months after last participant's first treatment

  10. Trough observed plasma concentration (Ctrough) for BMS-986012

    Time frame: Up to 19 months after last participant's first treatment

  11. Concentration at the end of a dosing interval (Ctau) for BMS-986012

    Time frame: Up to 19 months after last participant's first treatment

  12. Average concentration over a dosing interval ([AUC(TAU)/TAU]) (Cavg(TAU)) for BMS-986012

    Time frame: Up to 19 months after last participant's first treatment

  13. Area under the concentration-time curve within one dosing interval (AUC(TAU)) for BMS-986012

    Time frame: Up to 19 months after last participant's first treatment

  14. Total body clearance (CLT) for BMS-986012

    Time frame: Up to 19 months after last participant's first treatment

  15. Observed concentration at end of infusion (Ceoi) for BMS-986012

    Time frame: Up to 19 months after last participant's first treatment

Secondary outcomes

  1. Number of participants with anti-drug antibodies (ADAs) to BMS-986012

    Time frame: Up to 19 months after last participant's first treatment

  2. Number of participants with ADAs to nivolumab

    Time frame: Up to 19 months after last participant's first treatment

  3. Ctrough for nivolumab

    Time frame: Up to 19 months after last participant's first treatment

  4. Ceoi for nivolumab

    Time frame: Up to 19 months after last participant's first treatment

  5. Overall Response (OR)

    Achievement of best response of complete response (CR) or partial response (PR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, assessed by the investigator.

    Time frame: Up to 19 months after last participant's first treatment

  6. Disease Control (DC)

    Achievement of best response of CR or PR or stable disease (SD) using RECIST v1.1 criteria, assessed by the investigator.

    Time frame: Up to 19 months after last participant's first treatment

  7. Duration of Response (DOR)

    Time from first response (CR or PR) to first documented disease progression by investigator or death, whichever occurs first. For participants who did not have an event, the DOR will be censored on the date of their last tumor assessment.

    Time frame: Up to 19 months after last participant's first treatment

07

Study locations

5 sites
  • Local Institution - 0004
    Beijing, Beijing Municipality 100142, China
  • Local Institution - 0003
    Jinan, Shandong 250117, China
  • Local Institution - 0001
    Linyi, Shandong 276001, China
  • Local Institution - 0005
    Hangzhou, Zhejiang 310016, China
  • Local Institution - 0002
    Shanghai, 200120, China
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Sep 2026, 16 months.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's 16 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2025
First posted
Jan 29, 2025
StartActual
May 7, 2025
Primary completionActual
Sep 9, 2026
CompletionActual
Sep 9, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06799286
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
May 7, 2025
Primary completion
Sep 9, 2026
Completion
Sep 9, 2026
Last update
Sep 24, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atigotatug/Nivolumab

Start the discussion